Overview
Regular use of Systane COMPLETE in dry eye subjects before cataract surgery may optimize the ocular surface.
Description
Study details include:
- The study duration will be approximately 13 months for recruitment and 2 years of follow up from the last patient's initiation into the study.
- The induction treatment with osimertinib will be up to12 weeks, followed by 6 weeks of RT treatment and osimertinib maintenance treatment until disease progression or death.
- The visit frequency will be once after 12 weeks during the induction treatment period, every 3 weeks during the RT period (daily visits for RT), and every 12 weeks during the osimertinib maintenance treatment period.
Eligibility
Inclusion Criteria:
The subjects aged 20-85 years, with normal cognitive function and capable of answering related questionnaires who require phacoemulsification and intraocular lens implantation under topical anaesthesia, are the eligible candidates.
Exclusion Criteria:
- Unable to answer the questions in the dry eye survey.
- Ocular trauma or ocular surgery in the planned surgical eye, active ocular infection, and obvious abnormalities in ocular surface or eyelid margins other than MGD cause decreased visual acuity other than cataracts.
- Dry eye signs: Corneal Fluorescein Staining CFS (+) to exclude any corneal abnormalities or epithelial defect
- Systemic drug use, including tetracycline derivatives, antihistamines, and isotretinoin.
- Using dry eye medication at screening stage
